一、临床药理学与治疗学 (2023年第114卷第6期)

December 2023 - Volume 114 - Issue 6 (2023年12月第114卷第6期)
https://ascpt.onlinelibrary.wiley.com/toc/15326535/2023/114/6

Editorial（社论）
1. 确保临床药理学和治疗学临床试验报告的透明度和质量：所有临床试验都需要前瞻性试验注册并遵守报告指南
(Ensuring Transparency and Quality of Clinical Trial Reporting in Clinical Pharmacology & Therapeutics: Prospective Trial Registration and Compliance with Reporting Guidelines Are Required for all Clinical Trials)
作者：D. Max Smith* (MedStar Health, USA)

Perspective（视角）
1. 致幻剂和心理治疗：整体大于部分之和吗?
(Psychedelics and Psychotherapy: Is the Whole Greater than the Sum of its Parts?)
作者：Robert H. Dworkin* (Departments of Anesthesiology and Perioperative Medicine, Neurology, and Psychiatry, University of Rochester School of Medicine and Dentistry, USA)

White Paper（白皮书）
1. 利用OATP1B生物标志物Coproporphyrin-I指导药物-药物相互作用风险评估：来自制药行业的评估
(Utilization of OATP1B Biomarker Coproporphyrin-I to Guide Drug–Drug Interaction Risk Assessment: Evaluation by the Pharmaceutical Industry)
作者：Ryota Kikuchi, Bridget L. Morse* (Quantitative, Translational and ADME Sciences, AbbVie Inc., USA; Department of Drug Disposition, Eli Lilly, USA)

Reviews（综述）
1. 多发性骨髓瘤的CAR-T细胞疗法：以临床实践为导向的综述
(CAR T-Cell Therapy for Multiple Myeloma: A Clinical Practice-Oriented Review)
作者：Norah Layla Sadek, Sham Mailankody* (Department of Medicine, Mount Sinai Morningside and West, Icahn School of Medicine at Mount Sinai, USA; Department of Medicine, Cellular Therapy Service, Memorial Sloan Kettering Cancer Center, USA)
2. 人体吸收、代谢和排泄的变化形势：来自500项研究数据分析的实践经验
(The Changing Landscape for Human Absorption, Metabolism, and Excretion: Practical Experiences From a Data Analysis of 500 Studies)
作者：John S. Kendrick* (Labcorp Early Development Laboratories Inc., UK)

Systematic Review（系统综述）
1. 人类挑战研究的伦理要求：一项有关原因的系统综述
(Ethical Requirements for Human Challenge Studies: A Systematic Review of Reasons)
作者：Matthias Katzer* (Institute for Ethics, History, and Philosophy of Medicine, Hannover Medical School (MHH), Germany)

Tutorial（教程）
1. CYP2D6结构变异测试和报告建议的PharmVar教程
(PharmVar Tutorial on CYP2D6 Structural Variation Testing and Recommendations on Reporting)
作者：Amy J. Turner, Andrea Gaedigk* (Department of Pediatrics, Children's Research Institute, The Medical College of Wisconsin, USA; Children's Mercy Research Institute (CMRI), USA)

Research（研究）
1. 美国FDA针对妊娠期和哺乳期的新药进行的上市后承诺和要求描述
(Characterization of the US Food and Drug Administration Post-Marketing Commitments and Requirements for Pregnancy and Lactation)
作者：Charul Avachat, Angela K. Birnbaum* (Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, USA)

Articles（文章）
1. 建立4-吡啶酸PBPK模型，以支持OAT1 /3抑制和慢性肾脏疾病影响的生物标志物模型知情评估
(Development of 4-Pyridoxic Acid PBPK Model to Support Biomarker-Informed Evaluation of OAT1/3 Inhibition and Effect of Chronic Kidney Disease)
作者：Shawn Pei Feng Tan, Aleksandra Galetin* (Centre for Applied Pharmacokinetic Research, School of Health Sciences, University of Manchester, UK)
2. 基于生理学的炎症性肠病患者抗肿瘤坏死因子药物动力学模型预测妊娠停药时间和婴儿疫苗接种时间
(Physiologically-Based Pharmacokinetic Modeling of Anti-Tumor Necrosis Factor Agents for Inflammatory Bowel Disease Patients to Predict the Withdrawal Time in Pregnancy and Vaccine Time in Infants)
作者：Jiarui Chen, Cuihong Lin* (Department of Pharmacy, The First Affiliated Hospital of Fujian Medical University, China)
3. 肝硬化最小和全PBPK模型中肝门静脉血流分流的纳入和性能验证
(Incorporation and Performance Verification of Hepatic Portal Blood Flow Shunting in Minimal and Full PBPK Models of Liver Cirrhosis)
作者：Ben G. Small, Trevor N. Johnson* (Certara UK Limited (Simcyp Division), UK)
4. 美国生物类似药单克隆抗体免疫原性评价的研究
(Investigation of Immunogenicity Assessment of Biosimilar Monoclonal Antibodies in the United States)
作者：Ching-An Cheng, Lin-Chau Chang* (School of Pharmacy, College of Medicine, National Taiwan University, China)
5. 2016-2021年欧洲药品管理局评估的风险最小化措施有效性评估研究综述
(Review of Studies Evaluating Effectiveness of Risk Minimization Measures Assessed by the European Medicines Agency Between 2016 and 2021)
作者：Renske J. Grupstra, Helga Gardarsdottir* (Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Faculty of Science, Utrecht University, The Netherlands)
6. TICBase：药物和环境化学与哺乳动物药物转运蛋白相互作用数据的综合资源
(TICBase: Integrated Resource for Data on Drug and Environmental Chemical Interactions with Mammalian Drug Transporters)
作者：Matthew E. Michel, Sascha C. T. Nicklisch* (Department of Environmental Toxicology, University of California, USA)
7. 重症恶性疟疾患儿静脉注射青蒿琥酯的最佳剂量循证
(Evidence Based Optimal Dosing of Intravenous Artesunate in Children with Severe Falciparum Malaria)
作者：Ali Haghiri, Julie A. Simpson* (Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Australia)
8. 作为癌症终点的真实世界无进展生存：使用真实世界数据复制OAK试验的阿替利珠单抗组和多西他赛组
(Real-World Progression-Free Survival as an Endpoint in Lung Cancer: Replicating Atezolizumab and Docetaxel Arms of the OAK Trial Using Real-World Data)
作者：Shivani K. Mhatre, Michael T. Bretscher* (Genentech, Inc., USA; F. Hoffmann-La Roche Ltd., Switzerland)
9. Pegozafermin在非酒精性脂肪性肝炎患者中的群体药代动力学和药效学
(Population Pharmacokinetics and Pharmacodynamics of Pegozafermin in Patients with Nonalcoholic Steatohepatitis)
作者：Chih-Ming Leo Tseng* (Clinical Development, 89bio, Inc., USA)
10. ICH S7B体外检测未阐明肽和蛋白质的QTC延长机制—这些数据支持不需要专门的QTC研究
(ICH S7B In Vitro Assays Do Not Address Mechanisms of QTC Prolongation for Peptides and Proteins – Data in Support of Not Needing Dedicated QTC Studies)
作者：Wendy W. Wu* (Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Science, Center for Drug Evaluation and Research, FDA, USA)
11. 替格瑞洛在中国急性冠脉综合征患者中的模型引导给药方案
(Model-Informed Dosing Regimen of Ticagrelor in Chinese Patients With Acute Coronary Syndrome)
作者：Yaxin Liu, Cheng Cui* (Center of Clinical Pharmacology, The Third Xiangya Hospital, Central South University, China; Drug Clinical Trial Center, Center of Clinical Medical Research, Institute of Medical Innovation and Research, Peking University Third Hospital, China)
12.临床医生对药物遗传学临床决策支持警报的反应
(Clinician Response to Pharmacogenetic Clinical Decision Support Alerts)
作者：Lauren K. Lemke, Kristin Wiisanen* (Pharmacotherapy and Translational Research, University of Florida, USA)
13.阿片类药物处方及其相关严重不良事件的纵向轨迹：一项台湾人群队列研究
(Longitudinal Trajectory of Opioid Prescribing and its Associated Serious Adverse Events: A Population-Wide Cohort Study in Taiwan)
作者：Teng-Chou Chen, Chih-Peng Lin* (Centre for Pharmacoepidemiology and Drug Safety, Division of Pharmacy and Optometry, University of Manchester, UK; Department of Anesthesiology, National Taiwan University Hospital, China)
14.降脂药物对慢性肾病合并血脂异常患者肾脏和心血管预后的影响：一项回顾性队列研究
(Effect of Lipid-Lowering Drugs on Renal and Cardiovascular Outcomes in Patients with Chronic Kidney Disease and Dyslipidemia: A Retrospective Cohort Study)
作者：Yi-Chih Lin, Tai-Shuan Lai* (Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, China; Division of Nephrology, Department of Internal Medicine, National Taiwan University Hospital, China)
15.在III期POSEIDON研究中，CTLA-4抑制剂Tremelimumab在转移性NSCLC患者中的群体药代动力学和暴露-反应分析
(Population Pharmacokinetics and Exposure–Response Analysis for the CTLA-4 Inhibitor Tremelimumab in Metastatic NSCLC Patients in the Phase III POSEIDON Study)
作者：Jimmy Zhijian He, Diansong Zhou* (Clinical Pharmacology & Quantitative Pharmacology, BioPharmaceuticals R&D, AstraZeneca, USA)

二、药理学评论

（本刊为双月刊，每两月更新一次，详见2024年1月更新）

三、先进药物输送评论 (2023年第203卷)

December 2023 - Volume 203 (2023年12月第203卷)
https://www.sciencedirect.com/journal/advanced-drug-delivery-reviews/vol/203/suppl/C

Review article（综述文章）
1. 二氧化硅纳米颗粒：其安全性和当前克服生物屏障的策略综述
(Silica nanoparticles: A review of their safety and current strategies to overcome biological barriers)
作者：Taskeen Iqbal Janjua* (School of Pharmacy, The University of Queensland, Australia)
2. 组织再生和损伤反应中的炎症反应：细胞自主炎症信号如何介导细胞可塑性
(Transflammation in tissue regeneration and response to injury: How cell-autonomous inflammatory signaling mediates cell plasticity)
作者：John P. Cooke, Li Lai* (Department of Cardiovascular Sciences, Houston Methodist Research Institute, USA)
3. 你不必医治：通过改造炎症微环境来克服糖尿病足溃疡的不愈合行为
(Thou shall not heal: Overcoming the non-healing behaviour of diabetic foot ulcers by engineering the inflammatory microenvironment)
作者：Michael G. Monaghan, Shane Browne* (Department of Mechanical, Manufacturing and Biomedical Engineering, Trinity College Dublin, Ireland; CÚRAM, Centre for Research in Medical Devices, National University of Ireland, Ireland)
4. 传统途径的新兴药物递送系统—慢性炎症性疾病的路标
(Emerging drug delivery systems with traditional routes – A roadmap to chronic inflammatory diseases)
作者：Kiyoon Min, Giyoong Tae* (School of Materials Science and Engineering, Gwangju Institute of Science and Technology (GIST), Korea)
5. 口服纳米药物在胃肠道健康和疾病中的生物相互作用
(Oral nanomedicine biointeractions in the gastrointestinal tract in health and disease)
作者：Cheng Chen, Ana Beloqui* (UCLouvain, Université catholique de Louvain, Louvain Drug Research Institute, Advanced Drug Delivery and Biomaterials, Belgium)
6. 纳米载体通过胃肠道屏障运输：通过血液循环和淋巴途径对口服药生物利用度的贡献
(Nanocarriers transport across the gastrointestinal barriers: The contribution to oral bioavailability via blood circulation and lymphatic pathway)
作者：Ding Wang, Hong Yuan* (College of Pharmaceutical Science, Zhejiang University, China)
7. 纳米药物治疗罕见神经系统疾病：以克拉伯病为例
(Nanomedicines to treat rare neurological disorders: The case of Krabbe disease)
作者：Thomas Lee Moore* (Laboratory of Nanotechnology for Precision Medicine, Istituto Italiano di Tecnologia, Italy)
8. 用于长效胰岛素治疗的注射系统
(Injectable systems for long-lasting insulin therapy)
作者：Kumar Kulldeep Niloy, Tao L. Lowe* (Department of Pharmaceutical Sciences, University of Tennessee Health Science Center, USA)
9. 基于CAR-T细胞的免疫治疗的细胞和分子成像
(Cellular and molecular imaging of CAR-T cell-based immunotherapy)
作者：Longwei Liu* (Alfred E. Mann Department of Biomedical Engineering, University of Southern California, USA)
10. 用于智能药物递送和诊断的超声激活和皮肤相关的微创微型设备
(Ultrasound-activatable and skin-associated minimally invasive microdevices for smart drug delivery and diagnosis)
作者：Qi Zeng, Wei Chen* (Department of Pharmacology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, China)
11. 靶向递送抗癌治疗的脂质纳米颗粒：siRNA和脂蛋白模拟纳米载体的最新进展
(Lipid nanoparticles for targeted delivery of anticancer therapeutics: Recent advances in development of siRNA and lipoprotein-mimicking nanocarriers)
作者：Anan Yaghmur, Huiling Mu* (Department of Pharmacy, University of Copenhagen, Denmark)
12. 纳米药物在实体肿瘤治疗中治疗效果的时空之旅
(The spatiotemporal journey of nanomedicines in solid tumors on their therapeutic efficacy)
作者：Mengmeng Qin, Binlong Chen* (State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, China; Beijing Key Laboratory of Molecular Pharmaceutics and New Drug Delivery System, School of Pharmaceutical Sciences, Peking University, China)
13. 缓释高分子微针的研制策略
(Strategies to develop polymeric microneedles for controlled drug release)
作者：Bo Zhi Chen, Hiroshi Uyama* (State Key Laboratory of Organic-Inorganic Composites, Beijing University of Chemical Technology, China; Department of Applied Chemistry, Graduate School of Engineering, Osaka University, Japan)
14. 利用病毒样药物颗粒克服生物屏障进行药物递送
(Overcoming biological barriers by virus-like drug particles for drug delivery)
作者：Yu-Ling Chen, Ying Xie* (State Key Laboratory of Natural and Biomimetic Drugs, Beijing Key Laboratory of Molecular Pharmaceutics and Drug Delivery Systems, and School of Pharmaceutical Sciences, Peking University, China)
15. mRNA纳米药物中的纳米生物相互作用：mRNA靶向递送的挑战和机遇
(Nano-bio interactions in mRNA nanomedicine: Challenges and opportunities for targeted mRNA delivery)
作者：Qimanguli Saiding, Seyoung Koo* (Center for Nanomedicine, Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital, Harvard Medical School, USA)
16. 含肽纳米制剂：皮肤屏障渗透和活性贡献
(Peptide-containing nanoformulations: Skin barrier penetration and activity contribution)
作者：Tingting Zhang, Keming Xu* (Department of Chemistry, China Pharmaceutical University, China)
17. 用于生物医学应用的工程类器官
(Engineered organoids for biomedical applications)
作者：Natan Roberto de Barros* (Terasaki Institute for Biomedical Innovation (TIBI), USA)
18. 针对自身免疫性疾病的免疫耐受疫苗
(Vaccines for immune tolerance against autoimmune disease)
作者：April Kim, James J. Moon* (Department of Pharmaceutical Sciences, University of Michigan, USA)
19. 诱导免疫耐受的细胞和生物材料递送策略
(Cell and biomaterial delivery strategies to induce immune tolerance)
作者：Brianna L. Scotland, Ryan M. Pearson* (Department of Pharmaceutical Sciences, University of Maryland School of Pharmacy, USA)
20. 吸入RNA药物治疗肺部疾病：疾病相关细胞和纳米生物相互作用
(Inhaled RNA drugs to treat lung diseases: Disease-related cells and nano–bio interactions)
作者：Mengjun Zhang, Dongmei Cun* (Wuya College of Innovation, Shenyang Pharmaceutical University, China)

四、药理学发展趋势 (2023年第44卷第12期)

December 2023 - Volume 44 - Issue 12 (2023年12月第44卷第12期)
https://www.cell.com/trends/pharmacological-sciences/issue?pii=S0165-6147(22)X0013-8

TrendsTalk（趋势论）
1. 作为在药理学相关职业中代表性不足的群体成员讨论了至关重要的问题
(Thriving as members of under-represented groups in pharmacology-related careers)
作者：Nathalie L. Momplaisir* (Department of Pharmacology, University of Michigan, USA)

Science & Society（科学与社会）
1. 探索宿主-病毒相互作用以改善针对埃博拉病毒的免疫治疗
(Exploring host–virus interaction to improve immunotherapy against Ebola virus)
作者：Dacquin M. Kasumba* (Institut National de Recherche Biomédicale, Democratic Republic of the Congo)

Spotlights（聚焦）
1. FGF23信号传导中的结构不对称性
(Structural asymmetry in FGF23 signaling)
作者：Shih-Hsien Liu, L. Darryl Quarles* (UT/ORNL Center for Molecular Biophysics, Oak Ridge National Laboratory, USA; Department of Medicine, College of Medicine, University of Tennessee Health Science Center, USA)

Forum（论坛）
1.人体皮肤芯片用于猴痘发病机制研究和临床前药物评价
(Human skin-on-a-chip for mpox pathogenesis studies and preclinical drug evaluation)
作者：Jia Zhu* (Department of Laboratory Medicine and Pathology, University of Washington School of Medicine, USA)

Opinions（意见）
1. 青光眼：基于NAD治疗干预的神经保护作用
(Glaucoma: neuroprotection with NAD-based therapeutic intervention)
作者：Alberto Chiarugi* (Section of Clinical Pharmacology and Oncology, Department of Health Sciences, University of Florence, Italy)
2. 双特异性T细胞接合物的发展：利用定量系统药理学
(Development of bispecific T cell engagers: harnessing quantitative systems pharmacology)
作者：Timothy Qi, Yanguang Cao* (Division of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, The University of North Carolina at Chapel Hill, USA)
3. 创伤管理的潜在治疗靶点
(Potential therapeutic targets for trauma management)
作者：Zizheng Li, Ou Qiao, Ning Li*, Yanhua Gong* (Institute of Disaster and Emergency Medicine, Medical School, Tianjin University, China)

Reviews（综述）
1. 除ferrostatin-1之外：铁死亡抑制剂的全面性综述
(Beyond ferrostatin-1: a comprehensive review of ferroptosis inhibitors)
作者：Camilla Scarpellini, Koen Augustyns* (Laboratory of Medicinal Chemistry, Faculty of Pharmaceutical, Biomedical and Veterinary Sciences, University of Antwerp, Belgium)
2. 揭示污染物的信号能力
(Unravelling the signaling power of pollutants)
作者：Ana L. Manzano-Covarrubias, Hong Yan, Martina Schmidt* (Department of Molecular Pharmacology, University of Groningen, The Netherlands)
3. 旧途径的新把戏：新兴的基于Notch的生物技术和疗法
(New tricks for an old pathway: emerging Notch-based biotechnologies and therapeutics)
作者：Elliot Medina, Daniel Antfolk* (Department of Immunology, Moffitt Cancer Center, USA)
4. 乳糜泻：机制和新兴疗法
(Celiac disease: mechanisms and emerging therapeutics)
作者：Harrison A. Besser, Chaitan Khosla* (Department of Chemistry, Stanford University, USA)
5. 癌症药物在自闭症谱系障碍中的再利用
(Cancer drug repurposing in autism spectrum disorder)
作者：Giorgia Pedini¹, Chin-Lin Chen², Claudia Bagni¹* (1. University of Rome Tor Vergata, Department of Biomedicine and Prevention, Italy; 2. University of Lausanne, Department of Fundamental Neurosciences, Switzerland)
6. 血清素GPCRs中的配体选择性热点
(Ligand selectivity hotspots in serotonin GPCRs)
作者：Icaro A. Simon, Walden E. Bjørn-Yoshimoto, David E. Gloriam* (Department of Drug Design and Pharmacology, University of Copenhagen, Denmark)
7. 糖尿病微血管并发症中的m6A表转录组修饰
(m6A epitranscriptomic modification in diabetic microvascular complications)
作者：Li-Chan Lin, Jing-Jing Yang* (Department of Anesthesiology and Perioperative Medicine, The Second Affiliated Hospital of Anhui Medical University, China; Department of Clinical Pharmacology, The Second Affiliated Hospital of Anhui Medical University, China)
8. 靶向感觉神经元GPCR治疗周围神经性疼痛
(Targeting sensory neuron GPCRs for peripheral neuropathic pain)
作者：Ankit Uniyal, Srinivasa N. Raja* (Division of Pain Medicine, Department of Anesthesiology and Critical Care Medicine, The Johns Hopkins University, USA)
9. 治疗性蛋白诱导免疫耐受的新方法
(Emerging approaches to induce immune tolerance to therapeutic proteins)
作者：Justine C. Noel, Daniel Lagassé, Zuben E. Sauna* (Division of Hemostasis, Office of Plasma Protein Therapeutics, Center for Biologics Evaluation and Research, FDA, USA)

Drug of the Month（本月最佳药物）
1. ASO药物Qalsody（tofersen）靶向肌萎缩性侧索硬化症
(ASO drug Qalsody (tofersen) targets amyotrophic lateral sclerosis)
作者：Jing Jin, Xiao-bo Zhong* (Department of Pharmaceutical Sciences, School of Pharmacy, University of Connecticut, USA)

五、药理学与治疗学 (2023年第252卷)

December 2023 - Volume 252 (2023年12月第252卷)
https://www.sciencedirect.com/journal/pharmacology-and-therapeutics/vol/252/suppl/C

Review article（综述文章）
1. 多靶点抗菌药物：对抗细菌耐药性的有效策略
(Multitarget antibacterial drugs: An effective strategy to combat bacterial resistance)
作者：Jin Feng, Xu Wang* (National Reference Laboratory of Veterinary Drug Residues (HZAU) and MAO Key Laboratory for Detection of Veterinary Drug Residues, Huazhong Agricultural University, China)
2. 治疗严重哮喘及以上疾病的生物制剂
(Biologics for severe asthma and beyond)
作者：Carlo Mümmler, Katrin Milger* (Department of Medicine V, LMU University Hospital, Germany)
3. 免疫细胞作为肺纤维化驱动因素的新作用
(Emerging role of immune cells as drivers of pulmonary fibrosis)
作者：Steven E. Mutsaers* (Institute for Respiratory Health, The University of Western Australia, Australia)
4. 从探索癌症和病毒靶点到通过mRNA展示发现活性肽
(From exploring cancer and virus targets to discovering active peptides through mRNA display)
作者：José Brango-Vanegas, Octávio Luiz Franco* (Centro de Análises Proteômicas e Bioquímicas, Programa de Pós-Graduação em Ciências Genômicas e Biotecnologia, Universidade Católica de Brasília, Brazil)
5. 衰老过程中重要的是发出响应信号
(What matters in aging is signaling for responsiveness)
作者：Sang Chul Park* (The Future Life & Society Research Center, Advanced Institute of Aging Science, Chonnam National University, Korea)
6. 类视黄醇X受体激动剂作为治疗癌症的免疫系统的选择性调节剂
(Retinoid X Receptor agonists as selective modulators of the immune system for the treatment of cancer)
作者：Ana S. Leal, Karen T. Liby* (Department of Pharmacology and Toxicology, Michigan State University, USA)

六、药物 (2023年第83卷第18期)

December 2023 - Volume 83 - Issue 18 (2023年12月第83卷第18期)
https://link.springer.com/journal/40265/volumes-and-issues/83-18

Review Article（综述文章）
1. 治疗子宫肌瘤当前和新兴的治疗方案
(Current and Emerging Treatment Options for Uterine Fibroids)
作者：Mohamed Ali, Ayman Al-Hendy* (Department of Obstetrics and Gynecology, University of Chicago, USA)
2. HIV暴露前预防：应对HIV盛行的新药物和即将推出的药物
(HIV Pre-Exposure Prophylaxis: New and Upcoming Drugs to Address the HIV Epidemic)
作者：Christina G. Rivera, Zelalem Temesgen* (Section of Infectious Diseases, HIV Program, Mayo Clinic, USA)

Original Research Article（原创研究文章）
1. 应用更新的RUCAM对暴露于Elexacaftor/Tezacaftor/Ivacaftor的囊性纤维化患者的单中心队列中显著肝脏检查异常的病因学
(Aetiology of Significant Liver Test Abnormalities in a Single-Centre Cohort of People with Cystic Fibrosis Exposed to Elexacaftor/Tezacaftor/Ivacaftor, Utilizing the Updated RUCAM)
作者：Daniel Tewkesbury, Peter J. Barry* (Manchester Adult Cystic Fibrosis Centre, Wythenshawe Hospital, Manchester University NHS Foundation Trust, UK)

AdisInsight Report（AdisInsight报告）
1. Momelotinib：首次获批
(Momelotinib: First Approval)
作者：Susan J. Keam* (Springer Nature, New Zealand)
2.伊鲁阿克：首次获批
(Iruplinalkib: First Approval)
作者：Susan J. Keam (Springer Nature, New Zealand)
3.Gepirone缓释剂：首次批准
(Gepirone Extended-Release: First Approval)
作者：Susan J. Keam (Springer Nature, New Zealand)
4.Nedosiran：首次批准
(Nedosiran : First Approval)
作者：Yahiya Y. Syed (Springer Nature, New Zealand)

七、药理学研究 (2023年第198卷)

December 2023 - Volume 197 (2023年12月第198卷)
https://www.sciencedirect.com/journal/pharmacological-research/vol/198/suppl/C

Review Articles（综述文章）
1. 危险相关的代谢物引发代谢性炎症：心脏代谢疾病的一个关键因素
(Danger-associated metabolites trigger metaflammation: A crowbar in cardiometabolic diseases)
作者：Anlu Wang, Hao Xu* (Xiyuan Hospital, China Academy of Chinese Medical Sciences, China)
2. 在心血管疾病中，宿主-微生物之间的色氨酸分配
(Host-microbe tryptophan partitioning in cardiovascular diseases)
作者：Matteo Antonio Russo, Luigina Romani* (University San Raffaele and Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele, Italy)
3. 饮鸩止渴？抗癌药物的矛盾效应
(Quenching thirst with poison? Paradoxical effect of anticancer drugs)
作者：Kaiyuan Chai, Zhongqi Fan*, Guoyue Lv* (Department of Hepatobiliary and Pancreatic Surgery, General Surgery Center, First Hospital of Jilin University, China)
4. 纳米技术治疗癌症淋巴结转移：前路漫漫
(Nanotheranostics in cancer lymph node metastasis: The long road ahead)
作者：Kan Zhou, Bing Liu* (State Key Laboratory of Oral & Maxillofacial Reconstruction and Regeneration, Key Laboratory of Oral Biomedicine Ministry of Education, Hubei Key Laboratory of Stomatology, School & Hospital of Stomatology, Wuhan University, China)
5. 中性粒细胞作为乳腺癌的潜在治疗靶点
(Neutrophils as potential therapeutic targets for breast cancer)
作者：Yi-Ting Gong, Wei-Dong Zhang* (Shanghai Frontiers Science Center for Chinese Medicine Chemical Biology, Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, China)
6. 榄香烯注射液在癌症中的补充和替代作用：一项概括性综述
(The complementary and alternative roles of elemene injection in cancer: An umbrella review)
作者：Jixin Chen, Wanyin Wu* (The Second Clinical College of Guangzhou University of Chinese Medicine, China; State Key Laboratory of Dampness Syndrome of Chinese Medicine, Guangdong Provincial Key Laboratory of Clinical Research on Traditional Chinese Medicine Syndrome, Department of Oncology, Clinical and Basic Research Team of TCM Prevention and Treatment of NSCLC, Guangdong Provincial Hospital of Chinese Medicine, The Second Clinical College of Guangzhou University of Chinese Medicine, China)

Research article（研究文章）
1.人参皂苷Rh1是一种新的酪蛋白激酶II亚单位α (CK2α)抑制剂，通过破坏参与肿瘤细胞跨内皮屏障外渗的HHEX/CCL20信号级联来延缓转移
(Ginsenoside Rh1, a novel casein kinase II subunit alpha (CK2α) inhibitor, retards metastasis via disrupting HHEX/CCL20 signaling cascade involved in tumor cell extravasation across endothelial barrier)
作者：Weiwei Zheng, Aiyun Wang* (Jiangsu Key Laboratory for Pharmacology and Safety Evaluation of Chinese Materia Medica, School of Pharmacy, Nanjing University of Chinese Medicine, China)
2. 微生物源性短链脂肪酸对toll样受体7活化诱导的系统性红斑狼疮小鼠血管功能障碍的保护作用
(Protective effect of microbiota-derived short chain fatty acids on vascular dysfunction in mice with systemic lupus erythematosus induced by toll like receptor 7 activation)
作者：Javier Moleón, Iñaki Robles-Vera* (Department of Pharmacology, School of Pharmacy and Center for Biomedical Research (CIBM), University of Granada, Spain; Centro Nacional de Investigaciones Cardiovasculares (CNIC), Spain
3. RHBDF1缺乏抑制黑色素瘤糖酵解，并通过TRIM32促进葡萄糖-6-磷酸异构酶降解，从而提高免疫治疗的疗效
(RHBDF1 deficiency suppresses melanoma glycolysis and enhances efficacy of immunotherapy by facilitating glucose-6-phosphate isomerase degradation via TRIM32)
作者：Lei Wang, Lu-Yuan Li* (State Key Laboratory of Medicinal Chemical Biology and College of Pharmacy, the Haihe Laboratory of Cell Ecosystem, Tianjin Key Laboratory of Molecular Drug Research, Nankai University, China)
4. 人参皂苷Rh2通过增加肿瘤内CXCL10活化CD8+ T细胞增强抗pd - l1免疫治疗
(Ginsenoside Rh2 augmented anti-PD-L1 immunotherapy by reinvigorating CD8+ T cells via increasing intratumoral CXCL10)
作者：Mu-Yang Huang, Ting Li* (State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao Special Administrative Region of China)
5. 植物源性细胞外囊泡作为外源性miRNAs的纳米载体的治疗潜力
(Therapeutic potential of plant-derived extracellular vesicles as nanocarriers for exogenous miRNAs)
作者：María-Carmen López de las Hazas, Alberto Dávalos* (Laboratory of Epigenetics of Lipid Metabolism, Instituto Madrileño de Estudios Avanzados (IMDEA)-Alimentación, CEI UAM+CSIC, Spain)
6. 褪黑激素MT₁受体作为双相情感障碍精神药理学的靶点：一项转化研究
(Melatonin MT₁ receptors as a target for the psychopharmacology of bipolar disorder: A translational study)
作者：Margherita Tassan Mazzocco, Stefano Comai* (IRCCS San Raffaele Scientific Institute, Italy)
7. 可利霉素对肿瘤败血症患者炎症和免疫功能生物标志物的影响：一项多中心双盲随机对照试验
(Effects of carrimycin on biomarkers of inflammation and immune function in tumor patients with sepsis: A multicenter double-blind randomized controlled trial)
作者：Chuanchuan Nan, Kaijiang Yu* (Department of Critical Care Medicine, The First Affiliated Hospital of Harbin Medical University, China)
8. 组蛋白去乙酰化酶9通过表观遗传抑制Klotho加剧高同型半胱氨酸血症的足细胞损伤
(Histone deacetylase 9 exacerbates podocyte injury in hyperhomocysteinemia through epigenetic repression of Klotho)
作者：Min Liu, Ziying Wang* (Department of Pharmacology, School of Basic Medical Sciences, Shandong University, China)
9. 膜联蛋白-A1模拟物RTP-026通过调节免疫细胞激活促进急性心脏保护
(The Annexin-A1 mimetic RTP-026 promotes acute cardioprotection through modulation of immune cell activation)
作者：Jianmin Chen, Mauro Perretti* (William Harvey Research Institute, Queen Mary University of London, UK)
10. LSM1在乳腺癌中的作用：塑造代谢和肿瘤相关巨噬细胞浸润
(The role of LSM1 in breast cancer: Shaping metabolism and tumor-associated macrophage infiltration)
作者：Yen-Dun Tony Tzeng, Chia-Jung Li* (Department of Surgery, Kaohsiung Veterans General Hospital, China; Department of Obstetrics and Gynecology, Kaohsiung Veterans General Hospital, China)
11. 索拉非尼通过RBM20介导的肌体和线粒体基因的选择性剪接诱导心脏毒性
(Sorafenib induces cardiotoxicity through RBM20-mediated alternative splicing of sarcomeric and mitochondrial genes)
作者：Songming Liu, Jing-yan Han* (Department of Biomedical Informatics, School of Basic Medical Sciences, Peking University Health Science Center, China;Department of Integration of Chinese and Western Medicine, School of Basic Medical Sciences, Peking University, China )
12. 体积调节阴离子通道VRAC通过调节itaconate外排和线粒体功能来调节NLRP3炎性体
(The volume regulated anion channel VRAC regulates NLRP3 inflammasome by modulating itaconate efflux and mitochondria function)
作者：Xiaoyan Wu, Shiqing Zhang* (Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, China)
13. 非线性修饰增强了对肺癌术前PD-1阻断的病理反应的预测：一个纵向混合放射学模型
(Non-linear modifications enhance prediction of pathological response to pre-operative PD-1 blockade in lung cancer: A longitudinal hybrid radiological model)
作者：Weiqiu Jin, Jia Huang* (Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, China)
14. 探索无花果的药理多样性：调节经典免疫代谢及其他
(Exploring the pharmacological versatility of ficus carica: Modulating classical immunometabolism and beyond)
作者：Amene Saghazadeh* (Research Center for Immunodeficiencies, Children's Medical Center, Tehran University of Medical Sciences, Iran)

八、抗病毒研究 (2023年第220卷)

December 2023 - Volume 220 (2023年12月第220卷)
https://www.sciencedirect.com/journal/antiviral-research/vol/220/suppl/C

Research article（研究文章）
1. ZHX2的内含子遗传变异预测HBeAg阳性慢性乙型肝炎患者对聚乙二醇化干扰素α治疗的应答
(An intronic genetic variant of ZHX2 predicts response to pegylated interferon α therapy in HBeAg-positive chronic hepatitis B patients)
作者：Jia Hou, Jinlin Hou* (State Key Laboratory of Organ Failure Research, Guangdong Provincial Key Laboratory of Viral Hepatitis Research, Guangdong Institute of Liver Diseases, Department of Infectious Diseases and Hepatology Unit, Nanfang Hospital, Southern Medical University, China)
2. ASK1抑制剂是潜在的泛抗病毒药物，可以抑制包括SARS-CoV2在内的多种病毒的复制
(ASK1 inhibitors are potential pan-antiviral drugs, which dampen replication of diverse viruses including SARS-CoV2)
作者：Wael L. Demian, Karen Mossman* (Department of Medicine, McMaster University, Canada)
3. 人工智能：用于筛选大型数据库和药物发现的机器学习方法
(Artificial intelligence: Machine learning approach for screening large database and drug discovery)
作者：Prachi P. Parvatikar* (Department of Biotechnology, Allied Health Science, BLDE (Deemed-to-be University), India)
4. 在DAA治疗结束时检测到HCV RNA是否预示着治疗失败?
(Does a detectable HCV RNA at the end of DAA therapy herald treatment failure?)
作者：Dorota Zarębska-Michaluk,  Krystyna Dobrowolska* (Department of Infectious Diseases and Allergology, Jan Kochanowski University, Poland; Collegium Medicum, Jan Kochanowski University, Poland)
5. 携带变异特异性刺突蛋白的SARS-CoV-2单轮感染颗粒的感染性、药物敏感性和抗体中和功能评估
(Functional assessments of SARS-CoV-2 single-round infectious particles with variant-specific spike proteins on infectivity, drug sensitivity, and antibody neutralization)
作者：Wen-Chi Su, Michael M.C. Lai* (Graduate Institute of Biomedical Sciences, China Medical University, China)
6. 扩大抗黄病毒药物库：发现一种黄芩素衍生化合物对DENV和ZIKV具有有效活性。
(Expanding the anti-flaviviral arsenal: Discovery of a baicalein-derived Compound with potent activity against DENV and ZIKV.)
作者：Geraldine Nadya Putri, Shridhar Narayanan* (Infectious Diseases Translational Research Programme, Department of Microbiology and Immunology, Yong Loo Lin School, National University of Singapore, Singapore; Foundation for Neglected Disease Research, India)
7. SARS-CoV-2刺突蛋白受体结合域与IIb型大肠杆菌热不稳定肠毒素A亚基融合鼻内免疫诱导中和抗体和粘膜IgA
(Induction of neutralizing antibodies and mucosal IgA through intranasal immunization with the receptor binding domain of SARS-CoV-2 spike protein fused with the type IIb E. coli heat-labile enterotoxin A subunit)
作者：He-Chin Hsieh, Suh-Chin Wu* (Institute of Biotechnology, National Tsing Hua University, China)
8. 一种磺胺查尔酮通过病毒甲基转移酶的SAM结合位点上的潜在靶点抑制登革热病毒
(A sulfonamide chalcone inhibited dengue virus with a potential target at the SAM-binding site of viral methyltransferase.)
作者：Van Cao, Siwaporn Boonyasuppayakorn* (Center of Excellence in Applied Medical Virology, Department of Microbiology, Faculty of Medicine, Chulalongkorn University, Thailand)
9. 防己诺林碱抑制SARS-CoV-2和MERS-CoV的进入
(Fangchinoline inhibits SARS-CoV-2 and MERS-CoV entry)
作者：Srikanth Sadhu, Amit Awasthi* (Center for Immunobiology and Immunotherapy, Translational Health Science and Technology Institute, India)
10. 基于新城疫病毒（NDV）的SARS-CoV-2组粒鼻内免疫候选疫苗
(Newcastle Disease Virus (NDV)-based vaccine candidate against SARS-CoV-2 Omicron by intranasal immunization)
作者：Qiu-Yan Zhang, Han-Qing Ye* (Key Laboratory of Special Pathogens and Biosafety, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, China)
11. SRPKIN-1作为乙型肝炎病毒抑制剂阻断病毒颗粒形成和病毒感染的早期阶段
(SRPKIN-1 as an inhibitor against hepatitis B virus blocking the viral particle formation and the early step of the viral infection)
作者：Xiaofang Li, Tetsuro Suzuki* (Department of Microbiology and Immunology, Hamamatsu University School of Medicine, Japan)
12. RBD特异性合成抗体的二价形式可有效中和SARS-CoV-2变异株
(A bivalent form of a RBD-specific synthetic antibody effectively neutralizes SARS-CoV-2 variants)
作者：Dong-Gun Kim, Jeon-Soo Shin* (Department of Biological Sciences, Korea Advanced Institute of Science and Technology (KAIST), Korea; Department of Microbiology, Yonsei University College of Medicine, Korea)
13. K18-hACE2小鼠的肺转录组学揭示了MVA-S疫苗介导的免疫应答和预防SARS-CoV-2感染的机制和基因
(Lung transcriptomics of K18-hACE2 mice highlights mechanisms and genes involved in the MVA-S vaccine-mediated immune response and protection against SARS-CoV-2 infection)
作者：Alberto Gómez-Carballa, Antonio Salas* (Genetics, Vaccines and Infectious Diseases Research Group (Genvip), Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS), Spain)
14. tropolone吸收、代谢和清除率的体外评价
(In vitro evaluation of tropolone absorption, metabolism, and clearance)
作者：Molly E. Woodson, John E. Tavis* (Department of Molecular Microbiology and Immunology, Saint Louis University School of Medicine, USA)
15. 单糖基化SARS-CoV-2受体结合域与hastemm支架蛋白疫苗融合，可对SARS-CoV-2和流感病毒产生广泛的保护性免疫
(Monoglycosylated SARS-CoV-2 receptor binding domain fused with HAstem-scaffolded protein vaccine confers broad protective immunity against SARS-CoV-2 and influenza viruses)
作者：Chia-Ying Wu, Yung-Chieh Tseng, Juine-Ruey Chen* (RuenHuei Biopharmaceuticals Inc. China)
16. 一种吩噻嗪脲衍生物通过病毒蛋白酶抑制广泛抑制冠状病毒复制
(A phenothiazine urea derivative broadly inhibits coronavirus replication via viral protease inhibition)
作者：Katrina Forrestall, Sultan Darvesh* (Department of Medicine (Geriatric Medicine and Neurology) and Medical Neuroscience, Dalhousie University, Canada)
17. 单B细胞抗体技术在猪体内产生一种α冠状病毒的中和抗体
(Generation of whole-porcine neutralizing antibodies of an alphacoronavirus by single B cell antibody technology)
作者：Sheng Wang, Hongbo Zhou* (National Key Laboratory of Agricultural Microbiology, College of Veterinary Medicine, Huazhong Agricultural University, China)
18. 口服壳聚糖佐剂COVID-19疫苗可为金黄仓鼠提供持久和广谱的SARS-CoV-2变异株保护
(Oral delivery of a chitosan adjuvanted COVID-19 vaccine provides long-lasting and broad-spectrum protection against SARS-CoV-2 variants of concern in golden hamsters)
作者：Shen Wang, Xiaoqing Tang* (Key Laboratory of Jilin Province for Zoonosis Prevention and Control, Changchun Veterinary Research Institute, Chinese Academy of Agricultural Sciences, China; The First Affiliated Hospital, Hengyang Medical School, University of South China, China)
19. 对肠道病毒A71感染反应的蛋白质组学和磷酸化蛋白质组学分析揭示了抗病毒和病毒复制的新靶点
(Proteomic and phosphoproteomic analysis of responses to enterovirus A71 infection reveals novel targets for antiviral and viral replication)
作者：Dandan Lin, Xiaobo Lei* (NHC Key Laboratory of System Biology of Pathogens and Christophe Mérieux Laboratory, National Institute of Pathogen Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, China)

九、英国药理学杂志 (2023年第180卷第23-24期)

（一）December 2023 - Volume 180 - Issue 23 (2023年12月第180卷第23期)
https://bpspubs.onlinelibrary.wiley.com/toc/14765381/2023/180/23

Review Article（综述文章）
1.肾细胞癌中舒尼替尼耐药机制及相关治疗机会
(Mechanisms of sunitinib resistance in renal cell carcinoma and associated opportunities for therapeutics)
作者：Yunxia Wang, Weimin Cai* (School of Pharmacy, Fudan University, China)

Research Article（研究文章）
1. 抗惊厥药大麻二酚通过脂质暴露的孔域位点对人类KV7通道的亚型特异性调节
(Subtype-specific modulation of human KV7 channels by the anticonvulsant cannabidiol through a lipid-exposed pore-domain site)
作者：Michael Pökl, Sara I. Liin* (Department of Biomedical and Clinical Sciences, Linköping University, Sweden)
2. 生物钟在氯吡格雷时效和时毒性中的作用
(Role of circadian clock in the chronoefficacy and chronotoxicity of clopidogrel)
作者：Luyao Ma, Wangchun Li* (Institute of Molecular Rhythm and Metabolism, Guangzhou University of Chinese Medicine, China; The Affiliated Shunde Hospital of Jinan University, China)
3. 小分子成纤维细胞生长因子受体抑制剂infigratinib在多发性硬化症模型中具有抗炎和髓鞘再生的作用
(The small molecule fibroblast growth factor receptor inhibitor infigratinib exerts anti-inflammatory effects and remyelination in a model of multiple sclerosis)
作者：Ranjithkumar Rajendran, Martin Berghoff* (Experimental Neurology Group, Department of Neurology, University of Giessen, Germany)
4. 驱虫药硝唑尼特对实验性肺纤维化有保护作用
(Anthelmintic nitazoxanide protects against experimental pulmonary fibrosis)
作者：Xu-Yang Chen, Zhi-Jie Sun* (Department of Pharmacology (The State-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Research, Ministry of Education), College of Pharmacy, Harbin Medical University, China; Department of Pharmacology, China Pharmaceutical University, China)
5. 核黄素通过SCAD依赖性DJ-1–Keap1–Nrf2信号通路预防心力衰竭
(Riboflavin protects against heart failure via SCAD-dependent DJ-1–Keap1–Nrf2 signalling pathway)
作者：Qingping Xu, Sigui Zhou* (School of Chinese Materia Medica, Guangdong Pharmaceutical University, China)
6. Gβγ亚基信号传导是神经肽Y刺激的大鼠肠系膜和冠状动脉血管收缩的基础
(Gβγ subunit signalling underlies neuropeptide Y-stimulated vasoconstriction in rat mesenteric and coronary arteries)
作者：JinHeng Lin* (Department of Pharmacology, University of Oxford, UK)
7. Pamoic酸诱导的外周GPR35激活可改善瘙痒和皮炎
(Pamoic acid-induced peripheral GPR35 activation improves pruritus and dermatitis)
作者：Chaeeun Kim, Sun Wook Hwang* (Department of Biomedical Sciences and Department of Physiology, College of Medicine, Korea University, Korea)
8. Axin2的药理靶向抑制结直肠癌细胞生长和转移
(Pharmacological targeting of Axin2 suppresses cell growth and metastasis in colorectal cancer)
作者：Li-Zhi Cheng, Rong Fu* (State Key Laboratory of Natural Medicines, Department of Pharmacology, School of Pharmacy, China Pharmaceutical University, China)
9. 猪血脑屏障内皮细胞核受体对ATP结合盒式转运蛋白ABCB1、ABCG2和ABCC5的调控
(Regulation of the ATP-binding cassette transporters ABCB1, ABCG2 and ABCC5 by nuclear receptors in porcine blood–brain barrier endothelial cells)
作者：Yu Siong Ho, Pablo Torres-Vergara* (Division of Pharmacy and Optometry, School of Health Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, UK; Departamento de Farmacia, Facultad de Farmacia, Universidad de Concepción, Chile)

（二）December 2023 - Volume 180 - Issue 24 (2023年12月第180卷第24期)
https://bpspubs.onlinelibrary.wiley.com/toc/14765381/2023/180/24

Invited Review（特约综述）
1. 胰岛的肠道感受：肠道微生物组和短链脂肪酸FFA2和FFA3受体在β细胞功能和代谢调节中的作用
(Gut feelings in the islets: The role of the gut microbiome and the FFA2 and FFA3 receptors for short chain fatty acids on β-cell function and metabolic regulation)
作者：Razan Teyani, Nader H. Moniri* (Department of Pharmaceutical Sciences, College of Pharmacy, Mercer University Health Sciences Center, Mercer University, USA)

Research Articles（研究文章）
1. 单酰基甘油脂肪酶抑制剂MJN110对Marchigian撒丁岛嗜酒大鼠应激相关行为和饮酒的两性二态影响
(Sexually dimorphic effects of monoacylglycerol lipase inhibitor MJN110 on stress-related behaviour and drinking in Marchigian Sardinian alcohol-preferring rats)
作者：Valentina Vozella, Marisa Roberto* (Department of Molecular Medicine, The Scripps Research Institute, USA)
2. 强直性内源性大麻素信号的破坏会触发与应激反应一致的细胞、行为和神经内分泌反应
(Disruption of tonic endocannabinoid signalling triggers cellular, behavioural and neuroendocrine responses consistent with a stress response)
作者：Gavin N. Petrie, Matthew N. Hill* (Neuroscience Program, University of Calgary, Canada; Hotchkiss Brain Institute, University of Calgary, Canada)
3. 新型和经典阿片类药物诱导小鼠呼吸抑制的潜力评估
(Assessment of the potential of novel and classical opioids to induce respiratory depression in mice)
作者：Rob Hill, Meritxell Canals* (Division of Physiology, Pharmacology and Neuroscience, School of Life Sciences, Queen's Medical Centre, University of Nottingham, UK)
4. 血根碱通过减弱STAT3与单链DNA结合蛋白1（SSBP1）启动子区的结合诱导骨肉瘤细胞凋亡
(Sanguinarine induces apoptosis in osteosarcoma by attenuating the binding of STAT3 to the single-stranded DNA-binding protein 1 (SSBP1) promoter region)
作者：Kai-Di Wang, Ling-Yi Kong* (Jiangsu Key Laboratory of Bioactive Natural Product Research and State Key Laboratory of Natural Medicines, School of Traditional Chinese Pharmacy, China Pharmaceutical University, China)
5. 抑制Brd4通过抑制神经炎症和激活Nrf2介导的抗氧化信号来减轻骨关节炎疼痛
(Inhibition of Brd4 alleviates osteoarthritis pain via suppression of neuroinflammation and activation of Nrf2-mediated antioxidant signalling)
作者：Jia Sun, Ya-Qun Zhou* (Department of Anesthesiology, Xuzhou Central Hospital, China; Department of Anesthesiology, Hubei Key Laboratory of Geriatric Anesthesia and Perioperative Brain Health, and Wuhan Clinical Research Center for Geriatric Anesthesia, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, China)
6. 布拉氏酵母CNCM I-745作为预防非甾体抗炎药诱导的肠道损伤的治疗策略
(Use of Saccharomyces boulardii CNCM I-745 as therapeutic strategy for prevention of nonsteroidal anti-inflammatory drug-induced intestinal injury)
作者：Vanessa D'Antongiovanni, Matteo Fornai* (Department of Clinical and Experimental Medicine, University of Pisa, Italy)
7. SerpinB1在Rev-erbα介导、对脂多糖诱导的小鼠急性肺损伤的保护中起重要作用
(SerpinB1 is required for Rev-erbα-mediated protection against acute lung injury induced by lipopolysaccharide-in mice)
作者：Xue Xiao, Ziqing Hei* (Department of Anesthesiology, The Third Affiliated Hospital of Sun Yat-sen University, China)
8. 通过变构调节作用的新型鸟苷酸环化酶A活性增强剂
(Novel enhancers of guanylyl cyclase-A activity acting via allosteric modulation)
作者：Henriette Andresen, Finn Olav Levy* (Department of Pharmacology, Institute of Clinical Medicine, University of Oslo and Oslo University Hospital, Norway)
9. p38α MAP激酶的一种新型小分子抑制剂在直接细胞周期刺激下增强心肌细胞周期进入
(A novel small molecule inhibitor of p38αMAP kinase augments cardiomyocyte cell cycle entry in response to direct cell cycle stimulation)
作者：Riham R. E. Abouleisa, Tamer M. A. Mohamed* (Institute of Molecular Cardiology, Division of Cardiovascular Medicine, Department of Medicine, University of Louisville, USA)

十、临床药代动力学 (2023年第62卷第12期)

December 2023 -Volume 62 - Issue 12 (2023年12月第62卷第12期)
https://link.springer.com/journal/40262/volumes-and-issues/62-12

Review Article（综述文章）
1. N-乙酰氨基半乳糖结合小干扰核糖核酸（GalNAc共轭siRNA）的血浆药代动力学
(Plasma Pharmacokinetics of N-Acetylgalactosamine-Conjugated Small-Interfering Ribonucleic Acids (GalNAc-Conjugated siRNAs))
作者：Sebastian Sten¹, Tim Cardilin², Peter Gennemark¹* (1. Drug Metabolism and Pharmacokinetics, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Sweden; 2. Fraunhofer-Chalmers Research Centre for Industrial Mathematics, Sweden)
2. 非甾体盐皮质激素受体拮抗剂非奈利酮的药代动力学
(The Pharmacokinetics of the Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone)
作者：Roland Heinig* (Bayer AG, Research & Development, Pharmaceuticals, Translational Medicine, Germany)
3. 临床实践中艾沙康唑未结合部分的高变异性：重新考虑药代动力学/药效学目标和突破点的呼吁
(High Variability in Isavuconazole Unbound Fraction in Clinical Practice: A Call to Reconsider Pharmacokinetic/Pharmacodynamic Targets and Breakpoints)
作者：Anouk M. E. Jansen* (Department of Pharmacy, Radboud university Medical Center, Radboud Institute for Medical Innovations, The Netherlands)

Original Research Article（原创研究文章）
1. 危重患者总剂量和非结合剂量艾沙康唑的人群药代动力学：适应性给药策略的意义
(Population Pharmacokinetics of Total and Unbound Isavuconazole in Critically Ill Patients: Implications for Adaptive Dosing Strategies)
作者：Anouk M. E. Jansen* (Department of Pharmacy, Radboud University Medical Center, Radboud Institute for Medical Innovations, The Netherlands)
2. Zibotentan在并发中度肾功能和肝功能损害患者中的药代动力学和耐受性
(Pharmacokinetics and Tolerability of Zibotentan in Patients with Concurrent Moderate Renal and Moderate Hepatic Impairment)
作者：Anne-Kristina Mercier* (Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Sweden)
3. 地高辛在九十岁以上老年患者中的群体药代动力学：给药方案的优化
(Population Pharmacokinetics of Digoxin in Nonagenarian Patients: Optimization of the Dosing Regimen)
作者：Angel Luis Salcedo-Mingoarranz* (Pharmacy Department, Severo Ochoa University Hospital, Spain)
4. 非肽GnRH拮抗剂SHR7280在绝经前子宫内膜异位症患者中的安全性、药代动力学和药效学：一项随机、双盲、安慰剂对照的1期研究
(Safety, Pharmacokinetics, and Pharmacodynamics of SHR7280, a Non-peptide GnRH Antagonist in Premenopausal Women with Endometriosis: A Randomized, Double-Blind, Placebo-Controlled Phase 1 Study)
作者：Yuan Li¹, Ying Zheng, Qin Yu³* (1. Department of Obstetrics and Gynecology, Peking University Third Hospital, China; 2. Department of Gynecologic Oncology, West China Second University Hospital, Sichuan University, China; 3. Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education, China)
5. 纳武利尤单抗清除率对治疗早期非小细胞肺癌患者生存的预后价值
(Prognostic Value of Nivolumab Clearance in Non-Small Cell Lung Cancer Patients for Survival Early in Treatment)
作者：Leila S. Otten* (Department of Pharmacy, Radboud University Medical Center, The Netherlands)
6. 探讨细胞色素P450 2D6抑制对Ulotaront在健康受试者中的药代动力学影响，一项开放标签固定序列的I期研究
(A Phase I, Open-Label, Fixed Sequence Study to Investigate the Effect of Cytochrome P450 2D6 Inhibition on the Pharmacokinetics of Ulotaront in Healthy Subjects)
作者：Hironobu Tsukada, Gerald R. Galluppi* (Sumitomo Pharma America, USA)
7. 利特昔替尼群体药代动力学模型在临床药物开发中的演变
(Evolution of Ritlecitinib Population Pharmacokinetic Models During Clinical Drug Development)
作者：Jessica Wojciechowski* (Pfizer Inc., USA)